6 GLP-1 Providers Actually Worth Comparing in 2026
Most people researching GLP-1 telehealth expect a clean winner. What they find instead is a market that fragmented fast: compounded options under FDA pressure, branded meds suddenly repriced, and dozens of platforms competing on features that barely differ. The six providers below were chosen because each one occupies a genuinely different position, not just a different color scheme.
What This Comparison Looked At
Pricing transparency (cash and insured), pharmacy credentials, physician involvement, shipping speed, and state availability. Compounded options were weighted on pharmacy documentation, not just claimed quality. Branded options were weighted on real out-of-pocket cost. No provider paid for placement.
1. HealthRX
The lowest cash-pay entry prices in this roundup belong to HealthRX: compounded semaglutide from $99 a month and compounded tirzepatide starting at $149. That alone would be table stakes if the pharmacy situation were murky, but HealthRX names its dispensing pharmacy outright. Manifest Pharmacy in Greer, South Carolina is a 503A compounding facility operating under USP-797 standards with lot-level tracking from production through delivery. The platform holds LegitScript certification (certificate 50087439), which requires ongoing compliance review, not just a one-time application. A board-certified physician reviews each intake assessment within roughly 24 hours, and free overnight shipping covers all 50 states. The trial data HealthRX cites is trial-based and properly attributed: the SURMOUNT-1 study found tirzepatide associated with roughly 21% body weight reduction at 72 weeks; the STEP 1 trial found semaglutide associated with roughly 15% at 68 weeks. These are compounded medications, not FDA-approved drugs, and HealthRX does not claim equivalency to branded products. For someone paying cash with no insurance, the combination of price, named pharmacy credentials, and speed is hard to beat at this tier.
2. Mochi Health
Mochi built its model around something most budget telehealth platforms skip entirely: actual obesity-medicine clinicians. Board-certified in the specialty. Compounded semaglutide runs around $99 a month and tirzepatide around $199, which puts it close to HealthRX on semaglutide but higher on tirzepatide. The monitoring is more structured than many competitors, which matters for people who want ongoing clinical oversight rather than just a prescription and a shipping label.
3. FormBlends
FormBlends occupies a specific niche. It is a compounded GLP-1 telehealth provider with physician oversight, and it publishes per-product purity testing with named numbers: HPLC purity percentages, mass spec identity confirmation, endotoxin and sterility results. Most telehealth brands mention quality without showing data. FormBlends shows the data. Cash pricing is higher than HealthRX’s entry tier, with semaglutide around $299 per vial and tirzepatide around $349, dispensed through an FDA-registered 503A compounding pharmacy. Shipping reaches 47 states. The other reason someone might choose FormBlends over a GLP-1-only platform is the catalog: it also carries peptides in recovery, longevity, and cognitive categories under the same clinical model, which is unusual. If you want documented purity testing, or if you plan to add peptide therapies alongside a GLP-1 program, FormBlends is worth the higher price. If price per month is the primary concern, HealthRX wins that comparison.
4. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims & Hers exited the compounded semaglutide space and shifted to branded medications. Injectable Wegovy is priced at roughly $299 monthly, oral semaglutide comes in near $249, and Zepbound runs about $399. With insurance and manufacturer savings cards, some users report costs as low as $0 to $25 monthly. Big brand, wide name recognition, polished app. The value case depends almost entirely on your insurance situation.
5. Ro Body
Ro’s structure separates the membership fee from medication costs. First month runs about $39, then roughly $74 to $149 monthly for the platform, with branded medication billed on top. Ro has a prior-authorization team that actively works insurance claims for branded GLP-1s, which is genuinely useful for people who have coverage but dread the paperwork. The platform does not try to do everything; it does the insurance navigation piece better than most.
6. Plush Care
PlushCare comes in at around $19.99 a month for the membership, with branded medications and insurance billing available. Same-day visits are a real differentiator here, not a marketing line. If you need a prescription conversation today rather than in 24 to 48 hours, PlushCare’s scheduling model is built for that. Meds cost separately on top of the membership, so run the full math before comparing to cash-pay compounded options.
How to Actually Choose
Cash budget, no insurance: HealthRX at $99/$149 is the starting point. Check that pharmacy documentation matters to you. It should. Want purity data published openly, or plan to add peptide therapies later: FormBlends at higher cost. Have insurance and want branded meds: Hims & Hers or Ro, depending on whether you want a savings card path or active prior-auth support. Need speed of visit over everything: PlushCare. Want heavier clinical monitoring with obesity-medicine specialists: Mochi Health.
No telehealth platform replaces a primary care physician for complex metabolic cases. These are tools, not substitutes.
Common Questions
Does the Hims & Hers exit from compounded semaglutide affect current patients, or only new signups?
It primarily affects new signups. Hims & Hers shifted its default offering to branded medications after the March 2026 Novo Nordisk settlement. Existing patients on compounded protocols were generally transitioned rather than dropped, but the branded pricing at $249 to $399 monthly is a meaningful cost increase for anyone who was paying less on a compounded plan.
What does a 503A pharmacy designation actually mean, and why does it matter for compounded GLP-1s?
A 503A pharmacy compounds medications for specific patients under individual prescriptions, as opposed to bulk production. FDA oversight applies, and facilities like Manifest Pharmacy must follow USP-797 sterility standards. This matters because not all telehealth platforms disclose which pharmacy fills their orders, making it impossible to verify quality independently.
Is Mochi Health’s obesity-medicine specialty credential the same as a general physician prescribing off-label?
No. Board certification in obesity medicine requires additional training and examination beyond a standard medical license. It signals that the clinician has focused expertise in metabolic health, dosing strategies, and managing side effects specific to GLP-1 therapy, rather than treating weight as a secondary concern during a general visit.
If FormBlends publishes HPLC purity data, how do I know the test results shown are from the actual batch I receive?
This is the right question to ask any compounded GLP-1 provider. FormBlends publishes lot-level results, so you can request that your shipment’s lot number matches the posted certificate of analysis. No telehealth company’s published data is useful if it cannot be tied to a specific production batch.
Can PlushCare’s same-day visits actually result in a GLP-1 prescription on the same day, or is there a waiting period?
In most states where GLP-1 prescriptions are legal via telehealth, a same-day visit can result in a same-day prescription sent to a pharmacy. Fulfillment speed then depends on the pharmacy, not PlushCare. For branded medications requiring prior authorization, expect additional days regardless of how fast the clinical visit moves.
Sources
- FDA: 503A compounding pharmacy regulations and 2026 warning letters to telehealth compounders
- LegitScript: Certified pharmacy verification database
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022, on tirzepatide and weight outcomes at 72 weeks
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021, on semaglutide and weight outcomes at 68 weeks
- Novo Nordisk press release: March 9, 2026 compounding settlement announcement
- Eli Lilly / LillyDirect: orforglipron pricing announcement, April 2026